- Prev close
- $417.28
- Day range
- $405.50 – $420.42
Marriott’s move lines up with a strong earnings backdrop: Q3 beat-and-raise, RevPAR surged 6.5%, and the stock sits near its 52-week high at $410.98. The picture looks well-supported rather than driven by broad market noise.
MAR
MARRIOTT INTERNATIONAL -CL A
As of Nov 2, 2026
82/100
Looks healthyHealth ScorePrimary driver
MAR moved +4.3% in a session when the S&P 500 fell -1.8% and the Nasdaq 100 fell -3.5%, so the move is not explained by the broad tape. The main driver is stock-specific: the company just posted Q3 results that beat estimates, raised full-year outlook, and highlighted RevPAR surged 4.3%, which points to stronger operating momentum than the market was expecting.
Volatility read
This looks like a fundamental-driven move rather than ordinary noise. Revenue is up 4.3% YoY (TTM), the latest quarter was +4.8% YoY, EPS is up 4.3% YoY (TTM), and margins are still healthy at gross +19.8%, operating +15.8%, and net +9.6%; that is a solid base for a hotel operator. But the valuation is demanding at PE 40.2, forward PE 31.0, and PEG 3.23, so strong growth is already priced in and that can magnify swings in either direction. Beta is 1.15, which also says the shares should move a bit more than the market.
Earnings setup
The next earnings date is 2026-11-02. The facts provided do not include third-party consensus revenue or EPS estimates for that report, so I cannot cite an expected growth rate or margin forecast from this packet. What the market will be focused on is whether RevPAR strength can hold, whether fee growth and room additions keep supporting revenue, and whether Marriott can justify the raised 2026 guidance after a quarter that already delivered a beat and raise.
This report is for informational and educational purposes only. It does not constitute financial, investment, tax, or legal advice. The platform does not recommend buying or selling any security.
Track MAR with WhyIHold
Get a plain-English explanation the next time MARRIOTT INTERNATIONAL -CL A makes a big move — so you know whether it's benign or worth your attention.